Business & Economics

Pfizer has discontinued development of its early-stage immune-stimulating antibody conjugate (ISAC) PF-08046037, an investigational therapy targeting PD-L1, as part of a strategic realignment of its oncology pipeline. The decision, described as being for 'strategic business reasons' and not due to safety or efficacy concerns, comes after a series of notable clinical successes and high-profile deals that have reshaped Pfizer’s approach to cancer drug development.

Rakuten Medical is Developing ASP-1929 photoimmunotherapy Based on the Alluminox® Platform as a Selective Cancer Treatment with Focused Local Control

AbbVie Announces $1.4 Billion Manufacturing Campus in North Carolina: Largest Single-Site Investment in Company History

Recent Advances in the Clinical Development of First- and Best-in-Class Antibody-Drug Conjugates: Pipeline Update from Adcendo

The landscape of cancer treatment is rapidly evolving, driven by relentless innovation and a deepening understanding of tumor biology. Among the leading developers in this revolution is Byondis, an independent Dutch biopharmaceutical company with a bold mission: to deliver breakthrough solutions for patients with cancer through the creation of innovative, targeted medicines.

Gilead Accelerate Its Oncology ADC Pipeline by Acquiring Tubulis for $5B

Akari Therapeutics and WuXi XDC have announced a significant strategic partnership to accelerate the development and clinical entry of Akari’s lead ADC program, AKTX-101, which leverages PH1 (PH-1), a novel RNA splicing-modulating payload, for the treatment of metastatic urothelial cancer.

Economy: Failure to Reshore Pharmaceutical Manufacturing: US Approved Drug Manufacturing Shifts to Europe as US Deal Volume Drops

Samsung Biologics Expands Global Footprint with Acquisition of GSK’s Rockville Manufacturing Facility

The first patient (FIP) has been dosed in a Phase 1 clinical trial combining IDE849 (also known as SHR-4849), a potential first-in-class delta-like ligand 3 (DLL3)-targeting  Topoisomerase I (Topo-I-) payload antibody drug conjugate (ADC), with IDE161, a potential first-in-class poly(ADP-ribose) glycohydrolase (PARG) inhibitor. Both drugs are being developed by IDEAYA Biosciences. The Phase 1 combination study will be evaluated in DLL3 upregulated solid tumor indications, including small cell lung cancer (SCLC), neuroendocrine tumors (NETs), neuroendocrine carcinomas (NECs), and melanoma.